PLK1 and malignant colon neoplasm: The efficacy of this clinically most advanced PLK1 inhibitor has been demonstrated in different colon cancer models, and various phase I trials in solid tumors including colon cancer have shown favorable pharmacokinetics and manageable toxicity52.